Skip to main content

CAP TODAY/Dako Webinar: Introduction to PD-L1 interpretation in gastric cancer

Thank you

This live web event has ended. Thank you for attending.

Description

          

Introduction to PD-L1 interpretation in gastric
or gastroesphageal junction adenocarcinoma

Why should you register now for this webinar?

  • Brought to you by: CAP TODAY
  • Moderated by: Bob McGonnagle, Publisher, CAP TODAY
  • Presenters: Annika Eklund, PhD, and Debra Hanks, MD
  • FDA recently approved the use of Dako PD-L1 IHC 22C3 pharmDx as an aid in identifying gastric or gastroesophageal (GEJ) adenocarcinoma patients for treatment with KEYTRUDA® (pembrolizumab).
  • A new scoring method, Combined Positive Score, is introduced for testing in gastric or GEJ adenocarcinoma.
  • Learn about the FDA approval, background for PD-L1 testing in gastric or GEJ adenocarcinoma, and CPS scoring method.
  •  Ask your questions of our distinguished presenters.
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent Technologies.

Contributors

  • Bob McGonnagle

    Publisher, CAP TODAY

  • Annika Eklund, PhD

    Global Product Manager, Companion Diagnostics at Agilent Technologies
    PhD Pharmacology, Linköping University, Sweden, 2001
    MSc Molecular Biology, Umeå University, Sweden, 1995

  • Debra Hanks, MD

    Chief Pathologist, Companion Diagnostics Histopathology Department, Agilent Diagnostics and Genomics Division. US Board certified in Anatomic, Clinical, and Hematopathology. MD, University of California, San Francisco. BS, Medical Microbiology, Stanford University

October 17, 2017
Tue 1:00 PM EDT

Duration 1H 0M

This live web event has ended.

For Technical Support
support@blueskyelearn.com
+1 (858) 201-4136